SG11202008346PA - Nanoparticle compositions - Google Patents
Nanoparticle compositionsInfo
- Publication number
- SG11202008346PA SG11202008346PA SG11202008346PA SG11202008346PA SG11202008346PA SG 11202008346P A SG11202008346P A SG 11202008346PA SG 11202008346P A SG11202008346P A SG 11202008346PA SG 11202008346P A SG11202008346P A SG 11202008346PA SG 11202008346P A SG11202008346P A SG 11202008346PA
- Authority
- SG
- Singapore
- Prior art keywords
- nanoparticle compositions
- nanoparticle
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862637965P | 2018-03-02 | 2018-03-02 | |
US201962798859P | 2019-01-30 | 2019-01-30 | |
PCT/US2019/020389 WO2019169323A1 (en) | 2018-03-02 | 2019-03-01 | Nanoparticle compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202008346PA true SG11202008346PA (en) | 2020-09-29 |
Family
ID=67805547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202008346PA SG11202008346PA (en) | 2018-03-02 | 2019-03-01 | Nanoparticle compositions |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210038628A1 (en) |
EP (1) | EP3758495A4 (en) |
JP (1) | JP2021516227A (en) |
KR (1) | KR20200143365A (en) |
CN (1) | CN112218533A (en) |
AU (1) | AU2019227986A1 (en) |
CA (1) | CA3092834A1 (en) |
IL (1) | IL277017A (en) |
SG (1) | SG11202008346PA (en) |
WO (1) | WO2019169323A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111491634A (en) | 2017-07-31 | 2020-08-04 | 詹纽瑞治疗公司 | Organic phosphate derivatives |
US12110308B2 (en) | 2018-01-10 | 2024-10-08 | Nucorion Pharmaceuticals, Inc. | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds |
US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
AU2020263283A1 (en) * | 2019-04-22 | 2021-12-16 | Ligand Pharmaceuticals Incorporated | Cyclic phosphate compounds |
US12110311B2 (en) | 2019-07-17 | 2024-10-08 | Nucorion Pharmaceuticals, Inc. | Cyclic deoxyribonucleotide compounds |
US11708637B2 (en) | 2019-08-13 | 2023-07-25 | The Regents Of The University Of California | Methods of supporting a graphene sheet disposed on a frame support |
JP2023523415A (en) | 2020-04-21 | 2023-06-05 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Nucleotide prodrug compounds |
CN111544380B (en) * | 2020-05-12 | 2021-03-16 | 武汉大学 | Application of plasma replacement-free liquid composition in preparation of multiple myeloma M protein removing medicine |
MX2023002233A (en) | 2020-08-24 | 2023-03-15 | Gilead Sciences Inc | Phospholipid compounds and uses thereof. |
TWI811812B (en) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | Phospholipid compounds and uses thereof |
JP2023546565A (en) * | 2020-10-21 | 2023-11-06 | リガンド・ファーマシューティカルズ・インコーポレイテッド | antiviral prodrug compounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2874016B1 (en) * | 2004-06-30 | 2006-11-24 | Centre Nat Rech Scient Cnrse | NANOPARTICLES OF DERIVATIVES OF GEMCITABINE |
US20130131008A1 (en) * | 2011-10-25 | 2013-05-23 | Board Of Regents, The University Of Texas System | Lipophilic monophosphorylated derivatives and nanoparticles |
CA2952966A1 (en) * | 2014-06-24 | 2015-12-30 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
TWI678373B (en) * | 2014-10-31 | 2019-12-01 | 日商富士軟片股份有限公司 | Thionucleoside derivative or its salt and pharmaceutical composition |
WO2016188943A1 (en) * | 2015-05-27 | 2016-12-01 | Idenix Pharmaceuticals Llc | Nucleotides for the treatment of cancer |
CN104961786B (en) * | 2015-06-05 | 2018-09-25 | 苏州大学 | Pro-drug based on gemcitabine structure and its application |
CN111491634A (en) * | 2017-07-31 | 2020-08-04 | 詹纽瑞治疗公司 | Organic phosphate derivatives |
US20210346507A1 (en) * | 2018-08-20 | 2021-11-11 | Cure Biopharma Inc. | Gemcitabine prodrugs |
-
2019
- 2019-03-01 EP EP19760530.6A patent/EP3758495A4/en not_active Withdrawn
- 2019-03-01 AU AU2019227986A patent/AU2019227986A1/en not_active Abandoned
- 2019-03-01 US US16/976,909 patent/US20210038628A1/en not_active Abandoned
- 2019-03-01 CA CA3092834A patent/CA3092834A1/en active Pending
- 2019-03-01 SG SG11202008346PA patent/SG11202008346PA/en unknown
- 2019-03-01 KR KR1020207028193A patent/KR20200143365A/en unknown
- 2019-03-01 CN CN201980029880.6A patent/CN112218533A/en active Pending
- 2019-03-01 WO PCT/US2019/020389 patent/WO2019169323A1/en active Application Filing
- 2019-03-01 JP JP2020544946A patent/JP2021516227A/en active Pending
-
2020
- 2020-08-31 IL IL277017A patent/IL277017A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20200143365A (en) | 2020-12-23 |
CA3092834A1 (en) | 2019-09-06 |
US20210038628A1 (en) | 2021-02-11 |
CN112218533A (en) | 2021-01-12 |
EP3758495A4 (en) | 2021-12-01 |
JP2021516227A (en) | 2021-07-01 |
IL277017A (en) | 2020-10-29 |
EP3758495A1 (en) | 2021-01-06 |
WO2019169323A1 (en) | 2019-09-06 |
AU2019227986A1 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3665237T3 (en) | Compositions | |
IL277017A (en) | Nanoparticle compositions | |
GB201811312D0 (en) | Compositions | |
GB2586745B (en) | Compositions | |
IL261792B (en) | Compositions | |
IL260933A (en) | Plinabulin compositions | |
GB201610156D0 (en) | Cliptac compositions | |
SG11202009259VA (en) | Compositions | |
SG11202104306XA (en) | Compositions | |
GB201719480D0 (en) | Compositions | |
GB201707909D0 (en) | Compositions | |
EP3758490A4 (en) | Nanoparticle compositions | |
PT3765379T (en) | Compositions | |
GB201707454D0 (en) | Compositions | |
GB201614799D0 (en) | Compositions | |
PL3609464T3 (en) | Xanthohumol-based compositions | |
GB201622161D0 (en) | Compositions | |
IL269120A (en) | Compositions comprising avelumab | |
GB2570649B (en) | Compositions | |
GB201805676D0 (en) | Compositions | |
GB201717712D0 (en) | Compositions | |
GB201602658D0 (en) | Compositions | |
ZA202005658B (en) | Compositions | |
PT3768284T (en) | Compositions | |
GB201820233D0 (en) | Compositions |